Groupama Asset Management
RDY icon

Groupama Asset Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Groupama Asset Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,419
Closed -$778K – 444
2025
Q4 		$778K Buy
55,419
+912
+2% +$12.8K 0.01% 277
2025
Q3 		$762K Hold
54,507
– – 0.01% 299
2025
Q2 		$821K Buy
54,507
+948
+2% +$13.5K 0.01% 294
2025
Q1 		$707K Buy
+53,559
New +$739K 0.01% 298

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Groupama Asset Management's RDY Position: Q1 2026 in Review

Groupama Asset Management sold out of Dr. Reddy's Laboratories (RDY) in Q1 2026, closing a stake of 55,419 shares — an estimated $778K sold.

Groupama Asset Management first reported a position in RDY in Q1 2025 and held it in 4 quarters. The position peaked at $821K in Q2 2025. 249 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • Groupama Asset Management reported no remaining Dr. Reddy's Laboratories position as of Q1 2026 after selling out during the quarter.
  • Groupama Asset Management sold 55,419 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $778K.
  • Groupama Asset Management first reported a position in Dr. Reddy's Laboratories in Q1 2025 and held it in 4 quarters.
  • Groupama Asset Management's Dr. Reddy's Laboratories position peaked at $821K in Q2 2025.
  • 249 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on Groupama Asset Management's 13F filing for Q1 2026, filed 22 May 2026.